upcoming glp-1 drugs What to know about the new era of Study predicts 16 new obesity

Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Noureddin M, Alkhouri N, Younes R

A July 2024 study found that people who were taking semaglutide were about 4 times more likely to develop NAION compared to the control group

Alogliptin after acute coronary in patients in type 2 diabetes

Propensity-matched cohorts were analyzed to determine the relationship between the time of last Ozempic dose and anesthesia complications using multivariate logistic regression

As some researchers are looking at how they can deliver GLP-1s in vivo, others are looking beyond GLP-1 peptides altogether

What the $50 copay means in practice At $50 per month, the BALANCE copay represents a 95 percent reduction from list price